Trial Profile
A Phase II Study of Ibrutinib in Combination With Fludarabine, Cyclophosphamide, and Rituximab (iFCR) in Previously Untreated, Younger Patients With Chronic Lymphocytic Leukemia
Status:
Active, no longer recruiting
Phase of Trial:
Phase II
Latest Information Update: 12 Jan 2024
Price :
$35
*
At a glance
- Drugs Ibrutinib (Primary) ; Cyclophosphamide; Fludarabine; Rituximab
- Indications Chronic lymphocytic leukaemia
- Focus Therapeutic Use
- Acronyms iFCR
- 05 Jan 2024 Planned End Date changed from 1 Jan 2025 to 1 Jan 2026.
- 13 Sep 2023 Planned primary completion date changed from 1 Jan 2019 to 1 Jan 2025.
- 10 Mar 2022 Planned End Date changed from 1 Jan 2022 to 1 Jan 2025.